248 related articles for article (PubMed ID: 16083344)
1. Histone deacetylase inhibitors: insights into mechanisms of lethality.
Rosato RR; Grant S
Expert Opin Ther Targets; 2005 Aug; 9(4):809-24. PubMed ID: 16083344
[TBL] [Abstract][Full Text] [Related]
2. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors in clinical development.
Rosato RR; Grant S
Expert Opin Investig Drugs; 2004 Jan; 13(1):21-38. PubMed ID: 14680450
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of HDACs--effective drugs against cancer?
Müller S; Krämer OH
Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
[TBL] [Abstract][Full Text] [Related]
5. Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.
Cui Y; Cai J; Wang W; Wang S
Front Immunol; 2021; 12():690207. PubMed ID: 34149732
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitor-induced cell death in bladder cancer is associated with chromatin modification and modifying protein expression: A proteomic approach.
Li QQ; Hao JJ; Zhang Z; Hsu I; Liu Y; Tao Z; Lewi K; Metwalli AR; Agarwal PK
Int J Oncol; 2016 Jun; 48(6):2591-607. PubMed ID: 27082124
[TBL] [Abstract][Full Text] [Related]
7. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors as anti-neoplastic agents.
Batty N; Malouf GG; Issa JP
Cancer Lett; 2009 Aug; 280(2):192-200. PubMed ID: 19345475
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
10. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy.
Zhou M; Yuan M; Zhang M; Lei C; Aras O; Zhang X; An F
Eur J Med Chem; 2021 Dec; 226():113825. PubMed ID: 34562854
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors and rational combination therapies.
Grant S; Dai Y
Adv Cancer Res; 2012; 116():199-237. PubMed ID: 23088872
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
13. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
14. Focus on deacetylation for therapeutic benefit.
Shabbeer S; Carducci MA
IDrugs; 2005 Feb; 8(2):144-54. PubMed ID: 15696416
[TBL] [Abstract][Full Text] [Related]
15. The potential of histone deacetylase inhibitors in lung cancer.
Aparicio A
Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
Ranganna K; Selvam C; Shivachar A; Yousefipour Z
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
[TBL] [Abstract][Full Text] [Related]
17. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
19. Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.
Peng X; Sun Z; Kuang P; Chen J
Eur J Med Chem; 2020 Dec; 208():112831. PubMed ID: 32961382
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase Inhibitors Modulating Non-epigenetic Players: The Novel Mechanism for Small Molecule Based Therapeutic Intervention.
Ganai SA
Curr Drug Targets; 2018; 19(6):593-601. PubMed ID: 27231104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]